Recent developments include the proposed business combination with Applied Digital Corporation's cloud computing business, executive equity awards, and ongoing financial results reporting.

• On February 15, 2026, Ekso Bionics entered into a Contribution Agreement to acquire Applied Digital Corporation's cloud computing business, Applied Digital Cloud, in exchange for newly issued shares representing approximately 97% ownership of the combined company, subject to closing conditions [S2].
• The business combination is anticipated to close in the second quarter of 2026 but is subject to multiple conditions including regulatory approvals, cash requirements, and shareholder approvals [S2].
• The combination will cause significant dilution to existing stockholders, with legacy Ekso stockholders owning approximately 3% of the combined company post-closing [S2].
• On November 5, 2025, the company granted restricted stock units and phantom performance-based RSUs to key executives to retain and motivate them, with vesting tied to performance and change in control [S1].
• The company reported a net loss of $6.885 million and basic and diluted EPS of -$2.04 for the quarter ended March 31, 2026, with cash and cash equivalents of $3.993 million and a current ratio of 1.55 [S2].
• Federal funding and reimbursement policy changes have impacted customer purchasing ability, with potential further reductions posing risks to sales growth [S2].
• Supply chain challenges including shortages of electronic components and tariffs may increase costs and disrupt operations [S2].
• International sales expose the company to risks from foreign laws, regulations, currency fluctuations, and political instability [S2].

The company’s integration with Applied Digital Corporation's cloud computing business could create synergies and expand its technological capabilities, potentially enhancing product offerings and market reach. Continued improvements in product reliability and service efficiency may reduce costs and improve customer satisfaction. The executive team’s experience and incentive alignment may support strategic execution. Federal and private reimbursement policies, if favorable, could support sales growth. International expansion, if managed effectively, could diversify revenue streams.

Liquidity constraints and recurring operating losses raise concerns about the company’s ability to sustain operations without additional capital, which may be dilutive to shareholders. The business combination carries risks of integration failure, dilution, and adverse market reactions. Changes in federal funding and reimbursement policies could reduce customer purchasing power. Supply chain disruptions and tariff impacts may increase costs and affect margins. International market risks including regulatory, political, and currency challenges may limit growth. The company’s ability to reduce manufacturing costs and achieve profitability remains uncertain.

Ekso Bionics operates in the specialized niche of exoskeleton technology for medical and industrial use, which requires significant technological expertise and regulatory compliance. The company’s focus on product reliability, service support, and ongoing innovation contributes to its competitive positioning. However, the market is influenced by reimbursement policies, supply chain dynamics, and regulatory environments that may affect product adoption and cost structures. The company’s moat is supported by its technology platform and customer relationships, but it faces challenges from financial constraints and competitive pressures in a developing market.

• Liquidity and Capital Raising Risk: The company has recurring operating losses and limited cash resources, with liquidity concerns noted as of March 31, 2026. Additional capital raising may be required, which could be dilutive and may not be available on acceptable terms.
• Business Combination Risks: The proposed business combination with Applied Digital Corporation's cloud computing business is subject to multiple closing conditions and may not be completed on the current timeline or terms. The combination will cause significant dilution and carries integration and execution risks.
• Reimbursement and Funding Risks: The company’s sales depend in part on federal funding and reimbursement policies from government and private payors, which have experienced budget cuts and policy shifts that could reduce funding availability and impact sales.
• Supply Chain and Tariff Risks: Shortages of electronic components, battery cells, metals, and plastics, as well as changes in trade policies and tariffs, could increase costs, disrupt supply chains, and reduce profit margins.
• International Market Risks: International operations expose the company to risks from foreign laws, regulations, currency fluctuations, political instability, and differing reimbursement regimes, which may affect sales and operations.

• Ekso Bionics Holdings, Inc. is a company incorporated in Nevada with principal executive offices in San Rafael, California.
• The company develops and sells exoskeleton products primarily for medical and industrial applications.
• The company provides service and support for its products both in and out of warranty, aiming to maintain high standards.
• Ekso Bionics has experienced challenges in achieving profitability and sustaining positive cash flow, with recurring operating losses and cash burn.
• As of September 30, 2025, the company had cash of $2.7 million and an accumulated deficit of $257.7 million, indicating liquidity concerns.
• The company had cash and cash equivalents of $3.993 million as of March 31, 2026, with current assets of $14.053 million and current liabilities of $9.091 million, resulting in a current ratio of 1.55 and a cash ratio of 0.44.
• For the quarter ended March 31, 2026, the company reported a net loss of $6.885 million and basic and diluted EPS of -$2.04 per share.
• The company is pursuing a business combination with Applied Digital Corporation's cloud computing business, Applied Digital Cloud, which involves issuing a large number of shares and will result in significant dilution to existing stockholders.
• The business combination is subject to multiple closing conditions including regulatory approvals, cash requirements, and shareholder approvals, with no assurance of completion on the current timeline or terms.
• The combined company post-business combination will have the contributor owning approximately 97% of the equity, with legacy Ekso stockholders owning about 3%.
• The company faces risks related to integration of the new business, potential failure to realize expected benefits, and possible adverse market reactions.
• Ekso Bionics has granted equity awards to key executives to retain and motivate them, including restricted stock units and phantom performance-based RSUs with vesting conditions tied to performance and change in control.
• The company’s products depend in part on federal funding and reimbursement policies from government and private payors, including Medicare, Medicaid, and the Veterans Administration, which have experienced budget cuts and policy shifts affecting funding availability.
• The company faces supply chain risks including shortages of electronic components, battery cells, metals, and plastics, as well as risks from tariffs and trade policy changes that could increase costs or disrupt supply.
• International sales expose the company to risks from foreign laws, regulations, currency fluctuations, political instability, and differing reimbursement regimes.
• The company has a board of directors and executive officers with backgrounds in technology, finance, healthcare, and corporate governance, including CEO Scott G. Davis and CFO Jerome Wong.
• The company’s short-term incentive plan for executives is based on corporate performance goals including revenue, cash spend, product development, regulatory certifications, and strategic initiatives.
• The company’s financial figures and disclosures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.